Compare WMT & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMT | GILD |
|---|---|---|
| Founded | 1945 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 878.5B | 165.0B |
| IPO Year | 2012 | 2003 |
| Metric | WMT | GILD |
|---|---|---|
| Price | $103.64 | $146.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 29 | 18 |
| Target Price | $133.86 | ★ $148.39 |
| AVG Volume (30 Days) | ★ 22.8M | 6.3M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | 0.77% | ★ 2.55% |
| EPS Growth | 13.28 | ★ 1684.21 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $713,163,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $6.02 | $4.68 |
| Revenue Next Year | $4.47 | $6.04 |
| P/E Ratio | $155.20 | ★ N/A |
| Revenue Growth | 4.73 | ★ 9.98 |
| 52 Week Low | $95.42 | $108.46 |
| 52 Week High | $135.16 | $157.29 |
| Indicator | WMT | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 28.48 | 67.25 |
| Support Level | $98.88 | $142.93 |
| Resistance Level | $117.19 | $149.38 |
| Average True Range (ATR) | 2.33 | 4.26 |
| MACD | -0.80 | 1.23 |
| Stochastic Oscillator | 5.57 | 86.57 |
Since its founding in 1962, Walmart has become the world's largest retailer, operating over 10,700 stores globally (including 4,600 namesake locations on its home turf and another 600 Sam's Club outlets) and growing its e-commerce presence, attracting 270 million customers weekly. In aggregate, the firm posted more than $713 billion in fiscal 2026 sales. Its core operations span three reporting segments: Walmart US (68% of fiscal 2026 sales), Walmart International (19%), and Sam's Club (13%).Within the US, nearly 60% of its $486 billion in fiscal 2026 revenue came from its grocery offerings, with another quarter from general merchandise. Internationally, Walmart's operations are concentrated in Mexico, though it also has budding exposure to India.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).